AstraZeneca

AstraZeneca(AZN)

CAMBRIDGE, United Kingdom
Pharmaceutical4 H-1B visas (FY2023)

Focus: Small Molecules, Vaccines, Biologics

AstraZeneca is a life sciences company focused on Small Molecules, Vaccines, Biologics.

OncologyCardiovascularRespiratoryImmunologyRare Diseases
Funding Stage
PUBLIC
Employees
89,900
Open Jobs
1568

Products & Portfolio (18)

32 discontinued products not shown

AIRSUPRA
albuterol sulfate and budesonide
Peak
INHALATION · AEROSOL, METERED
Corticosteroid Hormone Receptor Agonists
asthma
2023
8
ARIMIDEX
anastrozole
LOE Approaching
SMORAL · TABLET
estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapybreast cancer
2008
30
BEVESPI AEROSPHERE
glycopyrrolate and formoterol fumarate
Peak
INHALATION · AEROSOL, METERED
fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD. Glycopyrrolate Glycopyrrolate is a long-acting antimuscarinic agent which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of the M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methylcholine and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted more than 12 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect. Formoterol Fumarate Formoterol fumarate is a long-acting selective beta 2 -adrenergic agonist (beta 2 -agonist) with a rapid onset of action. Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta 2 -receptors than at beta 1 -receptors. The in vitro binding selectivity to beta 2 - over beta 1 -adrenoceptors is higher for formoterol than for albuterol (5 times), whereas salmeterol has a higher (3 times) beta 2 -selectivity ratio than formoterol. Although beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, there are also beta 2 -receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta 2 -agonists may have cardiac effects. The pharmacologic effects of beta 2 -adrenoceptor agonist drugs, including formoterol fumarate, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
COPDasthmachronic obstructive pulmonary disease
2016
0
BEYFORTUS
nirsevimab
Growth
mAbINJECTION · INJECTABLE
Fusion Protein Inhibitors
RSV lower respiratory tract disease in: Neonatesinfants born duringentering their first RSV season
2023
30
BREZTRI AEROSPHERE
budesonide, glycopyrrolate, and formoterol fumarate
Peak
INHALATION · AEROSOL, METERED
Corticosteroid Hormone Receptor Agonists
COPDasthmachronic obstructive pulmonary disease
2020
0
BRILINTA
ticagrelor
Peak
ORAL · TABLET
P2Y12 Receptor Antagonists
cardiovascular (CV) deathmyocardial infarction (MI)stroke in patients with acute coronary syndrome (ACS)+5 more
2011
0
CALQUENCE
acalabrutinib
Peak
SMORAL · TABLET
Tyrosine Kinase Inhibitors
small lymphocytic lymphoma (SLL)lymphomaleukemia
2022
0
CALQUENCE
acalabrutinib
Peak
SMORAL · CAPSULE
Tyrosine Kinase Inhibitors
small lymphocytic lymphoma (SLL)lymphomaleukemia
2017
0
CASODEX
bicalutamide
LOE Approaching
ORAL · TABLET
12.1. Mechanism of Action CASODEX is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with LHRH analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with CASODEX as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted. In a subset of patients who have been treated with CASODEX and an LHRH agonist, and who discontinue CASODEX therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.
2008
30
CRESTOR
rosuvastatin
LOE Approaching
SMORAL · TABLET
HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
2003
30
DALIRESP
roflumilast
LOE Approaching
ORAL · TABLET
Phosphodiesterase 4 Inhibitors
COPD
2011
30
FARXIGA
dapagliflozin
Peak
ORAL · TABLET
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.
type 2 diabetes mellitustype 1 diabetes mellitusheart failure+1 more
2014
0
View all 18 products

Pipeline & Clinical Trials

Pre-COVID-19
Covid-19
N/A
Clinical Trials (2)
NCT05222750Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England
N/A
NCT05252442Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines
N/A
Questionnaires
Heart Failure
N/A
Clinical Trials (5)
NCT00734097A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Phase 4
NCT00777192Longitudinal Study of Symptoms in Colorectal Cancer
N/A
NCT01248507Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations
N/A

+2 more

A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Di
Gastroesophageal Reflux Disease
N/A
Clinical Trials (1)
NCT01215305A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
N/A
Bone Health Observational Study
Prostate Cancer
N/A
Clinical Trials (1)
NCT00632905Bone Health Observational Study
N/A
Clinical Trials (5)
NCT01443845Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
Phase 4
NCT01329029Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
Phase 4
NCT00424268Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
Phase 3

+2 more

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation
Non Small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT01081496Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
N/A
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of C
Chronic Obstructive Pulmonary Disease
N/A
Clinical Trials (1)
NCT01219946A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
N/A
Retrospective Study in a NSCLC M+ p
EGFR Mutated Non-small Cell Lung Cancer Patients
N/A
Clinical Trials (1)
NCT01795352Retrospective Study in a NSCLC M+ p
N/A
Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey
Diabetes
N/A
Clinical Trials (1)
NCT00916513Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey
N/A
Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )
Dyslipidemia
N/A
Clinical Trials (1)
NCT00526708Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )
N/A
Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidne
Chronic Kidney Disease (CKD)
N/A
Clinical Trials (1)
NCT06203704Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients
N/A
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmeno
Breast Cancer
N/A
Clinical Trials (1)
NCT00767585An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
N/A
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
Lung Neoplasms
N/A
Clinical Trials (1)
NCT01775943Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
N/A
Electronic Study for Anastrozole Pharmacovigilance Evaluation
Early Breast Cancer
N/A
Clinical Trials (1)
NCT00558168Electronic Study for Anastrozole Pharmacovigilance Evaluation
N/A
Dapagliflozin 10 milligrams [Farxiga]
Heart Failure
N/A
Clinical Trials (1)
NCT04591639The DAPA-MEMRI Trial
N/A
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Ast
Severe Asthma
N/A
Clinical Trials (1)
NCT04221802Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
N/A
General Practice Research Database Seroquel XR Safety Study
Schizophrenia
N/A
Clinical Trials (1)
NCT01447082General Practice Research Database Seroquel XR Safety Study
N/A
Dialog tool for caregivers
Asthma
N/A
Clinical Trials (1)
NCT00272727Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver
N/A
Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT06417801Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.
N/A
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced
NSCLC, Non-small-cell Lung Carcinoma
N/A
Clinical Trials (1)
NCT05456867A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
N/A
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Cor
Acute Coronary Syndrome
N/A
Clinical Trials (1)
NCT02408224An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
N/A
Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glom
Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images
N/A
Clinical Trials (1)
NCT04814680Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate
N/A
Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux
Patients With Typical Symptoms of GERD (GERD Q >= 8)
N/A
Clinical Trials (1)
NCT02606851Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.
N/A
A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, E
Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT04034992A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life
N/A
There are no interventions in this study. All participants complete online surveys.
Lung Cancer Patients
N/A
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egy
Neurofibromatosis Type 1
N/A
Clinical Trials (1)
NCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
N/A
Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
Non Small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT01167972Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma
N/A
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients Acco
Early Breast Cancer
N/A
AsthmaOptimiser-supported structured asthma review
Asthma Control
N/A
Clinical Trials (1)
NCT07390669OptimAIR: Towards Right Care in Asthma Through Point-of-care Phenotyping, Guideline-based Assessment and Management Optimalisation Using the AsthmaOptimiser in Primary Care
N/A
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Recepto
Postmenopause
N/A
Clinical Trials (1)
NCT01171417A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
N/A
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carci
Head and Neck Squamous Cell Carcinoma
N/A
Clinical Trials (1)
NCT06163534A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
N/A
AIRQ
Asthma
N/A
Clinical Trials (1)
NCT04891978US PRECISION Implementation Study
N/A
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data
Chronic Lymphocytic Leukemia
N/A
Clinical Trials (1)
NCT06548152AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
N/A
N/A
Clinical Trials (1)
NCT06851806Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
N/A
Clinical Trials (1)
NCT06862206This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
N/A
Study of Patient With Frequent COPD Exacerbations
Chronic Obstructive Pulmonary Disease (COPD)
N/A
Clinical Trials (1)
NCT07221981Study of Patient With Frequent COPD Exacerbations
N/A
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Dis
Chronic Obstructive Pulmonary Disease
N/A
Clinical Trials (1)
NCT02100332A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
N/A
N/A
Clinical Trials (2)
NCT02991274ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory
N/A
NCT03301493Genomic Testing and Resulting Medical Decisions
N/A
Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate C
Prostate Cancer
N/A
Clinical Trials (1)
NCT00523484Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts
N/A
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequenc
NSCLC
N/A
Clinical Trials (1)
NCT03609918Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
N/A
Clinical Trials (5)
NCT06099028Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China
N/A
NCT02803333Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study
N/A
NCT06172751TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
N/A

+2 more

Statin Therapy Results in the Real World Practice in the Czech Republic
Dyslipidaemia
N/A
Clinical Trials (1)
NCT01055977Statin Therapy Results in the Real World Practice in the Czech Republic
N/A
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in R
Chronic Obstructive Pulmonary Disease
N/A
Clinical Trials (1)
NCT06422676MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA
N/A
KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment
Antipsychotic Treatment
N/A
Clinical Trials (1)
NCT00750776KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment
N/A
An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT04072523An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients
N/A
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
Carcinoma, Small Cell
N/A
Clinical Trials (1)
NCT04854590IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
N/A
CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Con
Asthma
N/A
Clinical Trials (1)
NCT00714038CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.
N/A
N/A
Clinical Trials (5)
NCT00291408Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD
Phase 4
NCT04293445Asthma: Phenotyping Exacerbations 2
N/A
NCT05219773Clinic Versus Home Spirometry
N/A

+2 more

Seroquel XR in Schizophrenia Relapse Prevention
Schizophrenia Relapse Prevention
N/A
Clinical Trials (1)
NCT00990626Seroquel XR in Schizophrenia Relapse Prevention
N/A
Clinical Trials (5)
NCT01579916A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Phase 4
NCT00716963Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?
Phase 4
NCT01859143Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Phase 4

+2 more

Open Jobs (1568)

Senior Medical Representative

Eastern-Al Khobar
2d ago

Finance Business Analyst - Product Costing (18 months secondment/ FTC)

Poland - Warsaw
Finance
4d ago

Associate Director, Cell Therapy Territory Operations Manager

Boston - MA, US
4d ago
$150K - $225K/yr

Pharmaceutical Sales Specialist, Respiratory Specialty Care - Frederick, MD

Frederick - MD, US
4d ago
$107K - $160K/yr

Director, Project Toxicologist – Oncology Targeted Delivery Safety Science

Cambridge, UK
4d ago

Global Product Lead

Gaithersburg - MD, US
4d ago

RLL-Teze-西安/武汉

China
4d ago

Medical Representative_GP (North)

Taiwan
4d ago

Director, Policy and Assurance

Luton, UK
4d ago

SMM-Retail-上海

China
4d ago

NPP SMM(CVRM)-BBU new assets -上海

China
4d ago

Senior Scientist – Protein Design

Seattle - WA, US
4d ago

MSL – Hematology (Northern CA, NV, UT, S. ID, WY)

US
4d ago
$174K - $261K/yr

MSL – Hematology (North TX, CO, and NM)

US
4d ago
$174K - $261K/yr

Global Development Scientist Director

Waltham - MA, US
4d ago
$204K - $306K/yr

Sr. Compliance Specialist

Mexico - Guadalajara
4d ago

GMSLE ASSOCIATE DIRECTOR

Gaithersburg - MD, US
4d ago
$174K - $262K/yr

Propagandista Vendedor Respiratório - Ipatinga ou Governador Valadares/MG

Salesforce - Minas Gerais
4d ago

Director, Bioscience

Boston - MA, US
4d ago

Clinical Research Associate

Remote
4d ago

DSM-Retail-武汉

China
4d ago

Global Medical Head, Obesity

Boston - MA, US
4d ago
$283K - $425K/yr

合作营销经理-Eagle-济南

China
4d ago

合作营销经理-Eagle-合肥

China
4d ago

合作营销经理-Eagle-哈尔滨

China
4d ago
View all 1568 open positions →
Interview Prep Quick Facts
Portfolio: 110 approved products, 167 clinical trials
Top TAs: Oncology, Respiratory, Metabolic Diseases
H-1B (2023): 4 approvals
Publications: 25 in PubMed
Open Roles: 1568 active jobs
Portfolio Health
Pre-Launch23 (21%)
Growth5 (5%)
Peak29 (26%)
LOE Approaching45 (41%)
Post-LOE8 (7%)
110 total products
Therapeutic Area Focus
Oncology
11 marketed1409 pipeline
Respiratory
5 marketed647 pipeline
Metabolic Diseases
5 marketed361 pipeline
Cardiovascular
2 marketed326 pipeline
Neurology
3 marketed252 pipeline
Immunology
7 marketed116 pipeline
Nephrology
1 marketed114 pipeline
Gastroenterology
107 pipeline
Marketed
Pipeline

Hiring Trend

Actively Hiring
1568
Open Roles
+1569
Added
-1
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub